BioFocus, DiscoveRx Ink Co-Marketing Agreement | GenomeWeb

NEW YORK (GenomeWeb News) – BioFocus and DiscoveRx have signed a co-marketing pact that allows BioFocus to offer screening services using DiscoveRx's assay technologies, BioFocus said today.

Under the agreement, BioFocus, based in Saffron Walden, UK, will offer to its customers DiscoverX's PathHunter beta-arrestin GPCR assays, HitHunter cAMP assays, and associated cell lines.

"The addition of the DiscoveRx GPCR product portfolio to BioFocus will enhance our assay development and screening platform,” Chris Newton, senior vice president at BioFocus, said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: statistical approach to examine intra-tumor heterogeneity, new genetic condition called otulipenia, and more.

Blood tests looking for biomarker changes could catch mental illnesses earlier, Newsweek reports.

DNA testing offers Korean adoptees a way to find their birth parents that sidesteps bureaucratic red tape, according to the New York Times.

A National Institutes of Health researcher has filed an Equal Employment Opportunity complaint against the agency, the Washington Post reports.